/DWTX
DWTX Stock - Dogwood Therapeutics, Inc.
Healthcare|BiotechnologyNASDAQ
$6.45+5.74%
+$0.35 (+5.74%) • Dec 19
65
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.88
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.45
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $7.10
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for DWTX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$6.39 – $6.51
TARGET (TP)$7.42
STOP LOSS$5.93
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.88
52W High$29.28
52W Low$1.87
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-12,227,248 | $-5,446,919 | $-12,315,309 | $-15,640,940 | $-10,005,394 |
| Net Income | $-12,349,724 | $-5,296,015 | $-12,247,834 | $-15,960,268 | $-10,346,395 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-12.52 | $-7.05 | $-27.66 | $-47.90 | $-52.50 |
Company Overview
Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Virios Therapeutics, Inc. and changed its name to Dogwood Therapeutics, Inc. in October 2024. The company was founded in 2012 and is headquartered in Alpharetta, Georgia.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
DWTXBeat Rate
50%
Last 12 quarters
Avg Surprise
-113.4%
EPS vs Estimate
Beats / Misses
6/6
Last 12 quarters
Latest EPS
$-8.20
Q4 2025
EPS Surprise History
Q4 23
+18.2%
$-1.43vs$-1.75
Q2 24
+12.5%
$-0.07vs$-0.08
Q3 24
+28.6%
$-0.05vs$-0.07
Q4 24
-73.7%
$-2.05vs$-1.18
Q1 25
-333.6%
$-5.90vs$-1.36
Q2 25
-446.8%
$-4.21vs$-0.77
Q3 25
-57.9%
$-1.99vs$-1.26
Q4 25
-566.7%
$-8.20vs$-1.23
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 30, 2026 | $-1.22 | — | — | — |
Q4 2025 | Nov 6, 2025 | $-1.23 | $-8.20 | -566.7% | ✗ MISS |
Q3 2025 | Aug 13, 2025 | $-1.26 | $-1.99 | -57.9% | ✗ MISS |
Q2 2025 | May 8, 2025 | $-0.77 | $-4.21 | -446.8% | ✗ MISS |
Q1 2025 | Feb 26, 2025 | $-1.36 | $-5.90 | -333.6% | ✗ MISS |
Q4 2024 | Nov 7, 2024 | $-1.18 | $-2.05 | -73.7% | ✗ MISS |
Q3 2024 | Aug 8, 2024 | $-0.07 | $-0.05 | +28.6% | ✓ BEAT |
Q2 2024 | May 9, 2024 | $-0.08 | $-0.07 | +12.5% | ✓ BEAT |
Q4 2023 | Dec 31, 2023 | $-1.75 | $-1.43 | +18.2% | ✓ BEAT |
Q3 2023 | Sep 30, 2023 | $-2.25 | $-1.62 | +28.1% | ✓ BEAT |
Q2 2023 | Jun 30, 2023 | $-1.25 | $-1.96 | -56.5% | ✗ MISS |
Q1 2023 | Mar 31, 2023 | $-4.00 | $-2.07 | +48.3% | ✓ BEAT |
Q4 2022 | Dec 31, 2022 | — | $-2.79 | — | — |
Q3 2022 | Sep 30, 2022 | $-11.50 | $-7.00 | +39.1% | ✓ BEAT |
Q2 2022 | Jun 30, 2022 | — | $-11.01 | — | — |
Q1 2022 | Mar 31, 2022 | — | $-11.89 | — | — |
Q4 2021 | Dec 31, 2021 | — | $-13.54 | — | — |
Q3 2021 | Sep 30, 2021 | — | $-12.33 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-12.85 | — | — |
Q1 2021 | Mar 31, 2021 | — | $-9.18 | — | — |
Latest News
Dogwood Therapeutics Files For New Intellectual Property Protection For Synthetic Halneuron
📈 PositiveBenzinga•Dec 2, 2025, 01:04 PM
Dogwood Therapeutics Launches $8.56M At-The-Market Stock Offering Under New Equity Distribution Agreement
➖ NeutralBenzinga•Nov 28, 2025, 07:52 PM
Dogwood Therapeutics Enrolls First 100 Patients In Ongoing HALT-CINP Phase 2b CINP Trial
📈 PositiveBenzinga•Nov 11, 2025, 01:47 PM
Dogwood Therapeutics Q3 EPS $(8.20) Misses $(1.58) Estimate
📉 NegativeBenzinga•Nov 6, 2025, 01:50 PM
Dogwood Therapeutics Announces Its CMO Will Present An Overview Of The Halneuron Pain Management Research Program At 19th Annual Pain Therapeutics Summit On October 14, 2025
➖ NeutralBenzinga•Oct 7, 2025, 12:49 PM
HC Wainwright & Co. Maintains Buy on Dogwood Therapeutics, Raises Price Target to $12
📈 PositiveBenzinga•Sep 30, 2025, 11:07 AM
Market-Moving News for September 29th
➖ NeutralBenzinga•Sep 29, 2025, 11:20 AM•Also: ,
Dogwood shares are trading higher after the company secured a worldwide, royalty-free license to develop Serpin Pharma's SP16 IV formulation for cancer-related pain.
📈 PositiveBenzinga•Sep 29, 2025, 11:17 AM
Dogwood Therapeutics Secures Exclusive Worldwide, Royalty Free License To Develop Serpin Pharma's Intravenous Formulation Of SP16 For Cancer Related Pain; Serpin To Receive 382,034 Shares Of DWTX Common Stock And 179.1878 Of Preferred Stock
📈 PositiveBenzinga•Sep 29, 2025, 11:17 AM
Frequently Asked Questions about DWTX
What is DWTX's current stock price?
Dogwood Therapeutics, Inc. (DWTX) is currently trading at $6.45 per share. The stock has moved +5.74% today.
What is the analyst price target for DWTX?
No analyst price targets are currently available for this stock.
What sector is Dogwood Therapeutics, Inc. in?
Dogwood Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is DWTX's market cap?
Dogwood Therapeutics, Inc. has a market capitalization of $0.01 billion, making it a small-cap company.
Does DWTX pay dividends?
No, Dogwood Therapeutics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorBOLT
Bolt Biotherapeutics, Inc.
$5.16
Mkt Cap: $0.0B
BRTX
BioRestorative Therapies, Inc.
$1.15
Mkt Cap: $0.0B
CLRB
Cellectar Biosciences, Inc.
$2.68
Mkt Cap: $0.0B
COCP
Cocrystal Pharma, Inc.
$0.99
Mkt Cap: $0.0B
EDSA
Edesa Biotech, Inc.
$1.48
Mkt Cap: $0.0B
ERNA
Ernexa Therapeutics Inc.
$1.31
Mkt Cap: $0.0B
EVGN
Evogene Ltd.
$1.02
Mkt Cap: $0.0B
IMNN
Imunon, Inc.
$3.75
Mkt Cap: $0.0B
SNSE
Sensei Biotherapeutics, Inc.
$8.86
Mkt Cap: $0.0B
TRAW
Traws Pharma, Inc.
$1.27
Mkt Cap: $0.0B
Explore stocks similar to DWTX for comparison